NEO6860 / AazeinTx - LARVOL DELTA

adMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860) (Canada Newswire) - "adMare BioInnovations ('adMare') and AazeinTx Inc. ('AazeinTx') have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860...Based on Wilson's preclinical research, AazeinTx proposes to bring a pill-based form of NEO6860 to humans as a rapid, effective, and disruptive technology to treat asthma."

Licensing / partnership • Asthma • Respiratory Diseases

Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. (PubMed, Pharmacol Ther) - "We also conducted a meta-analysis of T data from human trials and found that polymodal TRPV1 antagonists (ABT-102, AZD1386, and V116517) increase T, whereas the mode-selective blocker NEO6860 does not. Several strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans are discussed."

Journal • Retrospective data • Review